Menu

MElAutim. Cancer and Autoimmunity

Cancer Immunotherapy. The hope and the risk

Picture
The development of immunotherapies, specially check point inhibitors (CPIs), has been one of the key achievements in recent times in our fight against cancer. In melanoma, CPIs have unprecedented response rates in up 60% of patients when anti-CTLA-4 anti-PD-1 therapies are combined. One can consider CPIs the actual 21st century cancer therapy.

However, this effectiveness comes with a price.  A large part of the patients treated with CPIs suffered severe autoimmune side effects in vital body organs. This includes lungs, bowel, joints and muscles, including heart.

Source: modified from Mikael Häggström, via Wikimedia https://commons.wikimedia.org/wiki/File:Internal_organs.png

 -Omics era profiling of patient samples to counterattack CPIs-induced autoimmunity

In MelAutim our aim is to improve our understanding of the molecular and cellular mechanisms underlying the interplay between autoimmunity and cancer immunotherapy. To this end, we profile patient samples with cutting-edge technologies for molecular profiling like DNA/RNA-Seq, transcriptomics and proteomics.

However, the amount of data generated and the complexity of the molecular and cellular mechanisms investigated pose a threat to our ability to understand. 



Picture

We profile molecularly blood and tissue samples from patient suffering CPIs-induced autoimmunity



Source: modified from Jonathan Bailey, NHGRI, via Wikimedia https://commons.wikimedia.org/wiki/File:Nanopore_Sequencing_(27820412495).jpg

Computational modelling and artificial intelligence. Our golden weapon  

To make possible the understanding of the data, in MelAutim we utilize computational modelling and artificial intelligence to reconstruct and simulate the molecular and cellular networks behind the CPIs-induced autoimmunity.  Our aim is to detect molecular signatures characterizing distinct groups of patients suffering the side effects.
We envision that this knowledge will help us designing personalized coadjuvant therapy to mitigate the autoimmune side effects of CPIs.


Picture

Simulation of a multi-level computational model of  melanoma micrometastasis under CPI therapy as conceived in MelAutim

Picture

This project is funded by the German Ministry of Research and Education (BMBF) under the e:Med program


Powered by Create your own unique website with customizable templates.
  • Home
  • Who we are
  • Publications
  • Home
  • Who we are
  • Publications